aTyr Pharma, Inc. $ATYR Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. reduced its stake in aTyr Pharma, Inc. (NASDAQ:ATYR) by 28.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,544,437 shares of the company’s stock after selling 4,122,163 shares during the period. Federated Hermes Inc. owned approximately 0.11% of aTyr Pharma worth $7,607,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ATYR. California State Teachers Retirement System purchased a new stake in shares of aTyr Pharma in the 2nd quarter valued at $28,000. Ameritas Investment Partners Inc. purchased a new stake in aTyr Pharma during the second quarter worth about $45,000. Main Street Financial Solutions LLC boosted its stake in shares of aTyr Pharma by 7.0% in the second quarter. Main Street Financial Solutions LLC now owns 143,600 shares of the company’s stock valued at $728,000 after purchasing an additional 9,350 shares during the period. Legal & General Group Plc acquired a new position in shares of aTyr Pharma in the second quarter valued at approximately $49,000. Finally, Raymond James Financial Inc. increased its stake in aTyr Pharma by 79.3% during the 2nd quarter. Raymond James Financial Inc. now owns 24,839 shares of the company’s stock worth $126,000 after buying an additional 10,989 shares during the period. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Stock Performance

Shares of aTyr Pharma stock opened at $0.88 on Monday. The company has a market capitalization of $86.51 million, a P/E ratio of -1.06 and a beta of 0.59. aTyr Pharma, Inc. has a 1 year low of $0.64 and a 1 year high of $7.29. The company’s fifty day moving average is $0.75 and its two-hundred day moving average is $2.16.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.06). The company had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.91 million. As a group, equities analysts expect that aTyr Pharma, Inc. will post -0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of aTyr Pharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $23.25.

aTyr Pharma Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.